Considerations for evaluating the impact of GLP‐1 receptor agonist use on inpatient outcomes
Abstract
Jessica L. Schwartz received grant funding from Novo Nordisk Inc for obesity-related research. This funding relationship has ended within the past 2 years. Michelle Ogunwole is supported by the National Institute of Diabetes and Digestive and Kidney Diseases through the DiabDocs K12 program (K12DK133995), the Robert A. Winn Clinical Investigator Leadership Award in Cardiovascular Research (Winn CILA-CV) from the American Heart Association, and the Johns Hopkins Center for Innovative Medicine. These sources had no role in this work, and the author reports no relevant conflict of interest.
Fields of Study & Subjects
Diabetes Treatment and Management
Heart Failure Treatment and Management
Pharmacology and Obesity Treatment
Publication details
- Journal / source
- Journal of Hospital Medicine
- Volume
- 21
- Issue
- 6
- Pages
- 685–686
- Publication date
- 12 February 2026
- Language
- EN